Bo Jan Noordman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4026228/publications.pdf

Version: 2024-02-01

		1163117	1372567
10	663	8	10
papers	citations	h-index	g-index
10 all docs	10 docs citations	10 times ranked	699 citing authors

#	Article	IF	CITATIONS
1	Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancer. Trials, 2021, 22, 345.	1.6	54
2	OUP accepted manuscript. British Journal of Surgery, 2021, , .	0.3	1
3	Accuracy of ¹⁸ F-FDG PET/CT in Predicting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer. Journal of Nuclear Medicine, 2019, 60, 1553-1559.	5.0	25
4	Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial. Journal of Clinical Oncology, 2018, 36, 268-275.	1.6	91
5	Oesophageal preservation in locally advanced oesophageal cancer – Authors' reply. Lancet Oncology, The, 2018, 19, e431.	10.7	3
6	Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncology, The, 2018, 19, 965-974.	10.7	211
7	Patients' preferences for treatment after neoadjuvant chemoradiotherapy for oesophageal cancer. British Journal of Surgery, 2018, 105, 1630-1638.	0.3	35
8	Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial. BMC Cancer, 2018, 18, 142.	2.6	166
9	Effect of lymphadenectomy on survival in oesophageal cancer. Nature Reviews Clinical Oncology, 2015, 12, 315-316.	27.6	8
10	Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol. JMIR Research Protocols, 2015, 4, e79.	1.0	69